Luye Pharma Group Ltd. (LUP.F)

0,3560 -0,0020 (-0,56%) Börsenschluss: 08:05AM CEST

Luye Pharma Group Ltd.

No. 15 Chuang Ye Road
High-tech Industrial Development Zone
Yantai 264003
China

https://www.luye.cn

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 5.270

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Dian Bo Liu	Co-Founder, Executive Chairman, CEO and Head of Corporate Directions & Strategies	538,31k	N/A	1966
Mr. Rong Bing Yang	Co-Founder & Vice Executive Chairman	398,06k	N/A	1966
Mr. Hui Xian Yuan	Co-Founder & Executive Director	187,76k	N/A	1959
Ms. Yuan Yuan Zhu	Executive Director	193,04k	N/A	1981
Mr. Yuan Chong Liu	Chief Financial Officer	N/A	N/A	1964

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Apleek Transdermal Patch for contraception; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders. In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Sailimai for acute and chronic diarrhea; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; research and development of antibody drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.

Corporate Governance

Luye Pharma Group Ltd.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 6. Die grundlegenden Scores sind Audit: 6, Vorstand: 3, Shareholderrechte: 7, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.